Your Messages Inbox
Your Article Summary
See Latest ArticlesNovel agent for treatment of Parkinson's disease - Lu 02-750 - enters Lundbeck's development pipeline
Lundbeck, 11/02/09
H. Lundbeck A/S strengthens its pipeline of pharmaceuticals in clinical development by initiating phase I clinical studies with Lu 02–750 in order to investigate safety, tolerability and the pharmacokinetic profile of the drug in humans. The placebo–controlled study is expected to enrol around 100 healthy individuals. Lu 02–750 is a dopaminergic agent acting on brain areas affected in Parkinson's disease. In animal models, the compound has demonstrated very convincing effects as compared to conventional treatments. Expectations are that the compound can offer Parkinson's patients a new and higher level of disease control.
Today in Medical Devices/Products...keeping you current
Receive free subspecialty "5-minute updates" via email
Chugai Revises Corporate Advertisement for First Time in Four Years
Chugai Pharmaceutical Co., 11/25/09
Huntington Hill Installs Toshiba Aquilion Premium CT
Imaging Economics, 11/25/09
Baytubes carbon nanotubes in marine coatings help reduce frictional resistance
BayNews International, 11/24/09
Today in Research & Development...keeping you current
Receive free subspecialty "5-minute updates" via email
Novartis inaugurates large-scale US based cell-culture influenza vaccine manufacturing facility
Novartis, 11/25/09
Bayer CropScience signs Agreement with GVK Biosciences on early-stage research projects
BayNews International, 11/25/09
Reports Rate Ambulatory EHR Software
HealthDataManagement, 11/25/09
Article Search
Sponsor